PHVS•Pharvaris said deucrictibant XR cut hereditary angioedema attack rates by 83% versus placebo in Phase 3, meeting its primary and all secondary efficacy endpoints.
Pharvaris said its investigational oral treatment deucrictibant XR cut hereditary angioedema attack rates by 83% versus placebo and met the trial’s primary and all secondary efficacy endpoints. Patients reported improved quality of life, and the treatment was generally well tolerated, with no treatment-related serious adverse events.
Pharvaris will present results from the Phase 3 CHAPTER-3 trial at the ACAAI meeting on Nov. 14, 2026.
